On 31st December 2019, the World Health Organization (WHO) China Country Office was informed of cases of pneumonia of unknown aetiology detected in Wuhan City, Hubei Province of China.(1) The first cases of COVID-19 outside of China were identified on January 30 in India and it has spread to 210 countries in all world regions by 10th April 2020, with more than 1.6 million confirmed and more than 0.1 million deaths worldwide.(2) Disasters and pandemics pose exceptional challenges to providing health care. Though telemedicine will not solve them all, it is well suited for scenarios in which medical practitioners can evaluate and manage patients. Previous work has specifically described the potential for using telemedicine in disasters and public health emergencies, wherein Patients prioritize convenient and inexpensive care, whether in-person visits becomes the last option for meeting patient needs.(3,4)

Globally, in 2015, measles killed an estimated 1,34,200 children - mostly under-5 years of age and an estimated 49,200 deaths occurred due to measles in India. Most of these children were the ones who have not received two doses of measles vaccine. This is despite the fact that the Government of India is providing vaccines free of cost under the Universal Immunization Programme. Even today some of the children in the country are not protected against the deadly life-threatening diseases. Some of these children are left unvaccinated because their parents are hesitant to immunise, believes that vaccines are dangerous. (1) There are many reasons for low vaccination coverage like lack of awareness or fear of side-effects of vaccination. Some of the times children are left unvaccinated because their parents receive wrong information about vaccination from a handful of people who keep trying to sabotage the vaccination programme in the country by giving factual figures and facts. (2) With digital age, social media and WhatsApp has become a new tool to spread rumours without even disclosing their identity. (3)

No abstract

0 1 7 ) A 3 9 9 -A 8 1 1 A717 objective of this study was to perform a systematic review of the most recent literature to better understand the efficacy and safety of current treatment for women with PPD. Methods: A systematic review of Medline, Embase, PsychInfo, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and several congresses was conducted according to the PRISMA Statement through February 2017 to identify literature on the treatment of PPD. Disease search terms included "postpartum depression", "postnatal depression", and "peripartum depression". Inclusion criteria included women with PPD aged ≥ 15 years treated in observational or interventional studies with any pharmacologic therapy. Results: In total, 889 unique studies were screened by two independent researchers by title and abstract; of these 58 full-text studies were evaluated and 31 were included in this review. In general, evidence supporting the efficacy of pharmacological therapies is limited; in particular, 3 placebo-controlled studies of 303 total patients did not report statistically significant improvements in various depression symptoms scores for nortriptyline or sertraline. In another study of 70 patients with PPD who were randomized to paroxetine or placebo, statistically significant improvements of pharmacologic therapy over placebo were shown for certain outcomes (e.g., proportion achieving remission by week 8, 37% vs. 15%; p = 0.04), whereas other measures of efficacy had borderline or non-significant differences between groups. Overall, evidence supporting the treatment of women with PPD is limited and complicated by variability in the study design and methods used to assess symptoms. ConClusions: Several treatments in women with PPD have been studied; however, evidence supporting the efficacy of these therapies is limited.